Management of Congenital Hypothyroidism: Evidence‑Based Recommendations

Initial Treatment Decisions

• Start levothyroxine at 10–15 µg/kg/day within the first 2 weeks of life to prevent irreversible neurocognitive impairment. 1
• Initiate therapy immediately when venous free T4 is below the age‑specific reference range. 2
• Initiate therapy immediately when venous TSH ≥ 20 mIU/L, even if free T4 is normal. 2
• Do not postpone treatment to obtain thyroid imaging; imaging may be performed after therapy has begun. 2

Weight‑Based Dosing

• For infants 0–3 months, prescribe 10–15 µg/kg/day (use the higher end for severe disease with very low pretreatment T4). 1
• In infants with pre‑existing cardiac insufficiency, start at 50 % of the target dose and increase gradually every 4–6 weeks. 3

Formulation and Administration

• Use brand‑name levothyroxine tablets in infancy, especially for severe cases, because bioequivalence with generics is not established. 4
• Crush tablets and suspend in a small amount of water or breast milk for administration to infants. 1
• Give the dose at the same time each day (morning or evening), either before or with feeding. 4
• Avoid concurrent intake of soy, iron, calcium, or simethicone‑containing products, as they impair levothyroxine absorption. 4

Monitoring Schedule

• First follow‑up laboratory assessment 1–2 weeks after treatment initiation. 2
• Until TSH normalizes, obtain thyroid function tests every 2 weeks. 2
• After TSH normalization and through 12 months of age, monitor every 1–3 months. 2
• Draw blood samples at least 4 hours after the last levothyroxine dose to avoid transient TSH suppression. 5
• Ages 1–3 years: clinical and laboratory evaluation every 2–4 months. 5
• After age 3 years until growth completion: monitoring every 3–12 months; increase frequency if compliance is doubtful, values are abnormal, or the dose/formulation changes. 5

Target Laboratory Values

• Maintain TSH within the age‑specific reference range and avoid undetectable levels (< 0.05 mIU/L). 4
• Keep free T4 (or total T4) in the upper half of the age‑specific reference range, especially during the first 3 years. 5
• Do not reduce levothyroxine dose based on a single isolated elevated free T4 measurement. 5

Importance of Early Hormone Normalization

• Achieving rapid normalization of thyroid hormone levels within the first 2 weeks is associated with better intellectual outcomes. 6

Re‑evaluation of Diagnosis

• Indications for re‑evaluation include: lack of diagnostic assessment in infancy (especially in preterm or ill infants), normal‑located gland on imaging, no dose increase since infancy, or presence of maternal thyroid antibodies. 3
• Re‑evaluation is not required when thyroid dysgenesis (ectopy or athyreosis) or confirmed dyshormonogenesis (except DUOX2 mutations or Pendred syndrome) has been documented. 3
• Perform re‑evaluation after age 3 years: phase out levothyroxine over 4–6 weeks, then obtain full biochemical and imaging studies; alternatively, reduce dose by 30 % for 2–3 weeks and confirm CH if TSH rises to ≥ 10 mIU/L. 5

Developmental and Associated Condition Monitoring

• Systematically monitor psychomotor development and school progress in all children, with heightened vigilance for high‑risk features (absent knee epiphyses at birth, very low initial T4, very high TSH, athyreosis, delayed TSH normalization, poor control in the first year, or delayed milestones). 5
• Examine all neonates with elevated TSH for congenital malformations, particularly cardiac defects, and for dysmorphic features. 5
• Consider a knee X‑ray to assess the severity of intrauterine hypothyroidism by evaluating femoral and tibial epiphyses. 5

Compliance and Quality of Life

• Promote lifelong adherence to levothyroxine therapy; suboptimal treatment in young adulthood is linked to reduced health‑related quality of life. 5
• Provide written instructions to parents to minimize uncertainties that may hinder compliance. 4
• Avoid labeling the child to nursery or school personnel unless medically necessary. 2

Special Situations

• After any switch from brand‑name to generic levothyroxine, re‑check thyroid function 4–6 weeks later. 3
• In females with congenital hypothyroidism who become pregnant, increase the levothyroxine dose by 25–30 % immediately upon a missed menstrual cycle or positive pregnancy test and monitor TSH every 4–6 weeks throughout pregnancy. 5

Levothyroxine Initiation, Dosing, and Monitoring in Infants with Congenital Hypothyroidism

Initiation and Initial Dosing

• Initiate levothyroxine therapy as soon as possible; treatment begun within the first 2 weeks of life markedly reduces the risk of irreversible neurocognitive impairment【7】.
• Start at a dose of 15 µg/kg/day (the higher end of the 10–15 µg/kg/day range) for infants presenting with markedly elevated newborn‑screen TSH (e.g., ≥ 24 mIU/L), reflecting more severe disease【7】.
• Use brand‑name levothyroxine tablets rather than generic formulations in severe congenital hypothyroidism because bioequivalence in this age group has not been established【7】.

Administration Considerations

• Administer the dose at the same time each day (morning or evening) and avoid concurrent intake of soy, iron, calcium, or simethicone‑containing products, which can impair levothyroxine absorption【7】.
• Monitor vitamin D status, as hypercalcemia has been reported during the first weeks of levothyroxine therapy【7】.

Early Monitoring (First Month)

• Perform the first laboratory assessment 1–2 weeks after therapy starts, measuring both TSH and free (or total) T4【7, 8】.
• Draw blood ≥ 4 hours after the last levothyroxine dose to avoid transient TSH suppression that can give falsely low values【7】.

Intensive First‑Year Monitoring

• Repeat TSH and T4 testing every 2 weeks until TSH normalizes; rapid normalization within the first 2 weeks is associated with better intellectual outcomes【7, 8, 9】.
• After TSH reaches the age‑specific reference range, continue monitoring every 1–3 months through 12 months of age【7, 8, 9】.
• From 1 to 3 years of age, test every 2–4 months; after age 3 until growth completion, test every 3–12 months【8, 9】.
• Increase monitoring frequency if there are concerns about adherence, abnormal laboratory values, or changes in dose/formulation【8, 9】.

Target Laboratory Goals

• Maintain TSH within the age‑specific reference range and avoid undetectable levels (< 0.05 mIU/L)【7, 8】.
• Keep free (or total) T4 in the upper half of the age‑specific reference range during the first 3 years to support optimal neurodevelopment【7, 8】.

Dose‑Adjustment Principles

• Do not reduce levothyroxine dose based on a single isolated elevated free T4; confirm the trend with repeat testing before making adjustments【7, 8】.
• Do not check TSH sooner than 4 hours after levothyroxine administration, as this can produce falsely suppressed results【7】.
• Avoid generic levothyroxine formulations in infants with severe congenital hypothyroidism, given concerns about bioequivalence【7】.

Long‑Term Outcomes and Follow‑Up

• Lifelong adherence to levothyroxine is essential; suboptimal treatment in young adulthood is linked to reduced health‑related quality of life【9】.
• With good adherence, normal growth, puberty, and fertility are expected【8】.
• Infants whose treatment is delayed (e.g., started at 1 month) and who had very high initial TSH are at higher risk for subtle neurocognitive deficits, necessitating close developmental surveillance【7】.

Re‑Evaluation After Age 3 (When Indicated)

• Re‑evaluate after age 3 if imaging shows a normal thyroid location and the child has required no dose increases since infancy【8】.

All statements are supported by peer‑reviewed evidence from the Journal of Clinical Endocrinology & Metabolism (2014) as cited.

Management of Congenital Hypothyroidism in Infants

Indication for Treatment

• Initiate levothyroxine therapy immediately (10–15 µg/kg/day) when free T4 is below the age‑specific reference range, confirming congenital hypothyroidism【10】.
• A newborn screen showing TSH ≥ 20 mIU/L, even with a normal T4, mandates prompt treatment to prevent neurodevelopmental injury【10】.
• The combination of an initial TSH of 24.1 mIU/L and T4 of 16.6 ng/dL indicates severe disease and requires urgent levothyroxine initiation【10】.

Choice of Levothyroxine Formulation

• Use brand‑name levothyroxine tablets rather than generic formulations because bioequivalence has not been demonstrated in severe congenital hypothyroidism in infants【11】.

Administration Technique

• Crush the tablet and suspend it in a small amount of water or breast milk before giving to the infant【11】.
• Administer the dose at the same time each day (morning or evening) and maintain consistency with respect to meals【11】.
• Avoid concurrent intake of soy, iron, calcium, or simethicone‑containing products at the time of levothyroxine dosing, as these impair absorption【11】.
• Monitor vitamin D supplementation carefully during the first weeks of therapy because prophylactic vitamin D has been associated with hypercalcemia in this setting【11】.

Monitoring Schedule

• Perform the first follow‑up laboratory assessment 1–2 weeks after treatment start, measuring both TSH and free T4【11】.
• Collect blood samples at least 4 hours after the last levothyroxine dose to avoid transient TSH suppression and false‑low results【11】.
• Repeat TSH and free T4 testing every 2 weeks until TSH normalizes; rapid normalization within the first 2 weeks correlates with improved intellectual outcomes【11】.
• Once TSH is within the age‑specific reference range, continue monitoring every 1–3 months through 12 months of age【11】.

Laboratory Targets

• Maintain TSH within the age‑specific reference range (approximately 1.9–10.3 mIU/L for a 1‑month‑old) and avoid undetectable levels (< 0.05 mIU/L)【11】.
• Keep free T4 in the upper half of the age‑specific reference range (≈ 1.5–2.0 ng/dL for a 1‑month‑old) to support optimal neurodevelopment【11】.
• Do not adjust the levothyroxine dose based on a single isolated elevated free T4; confirm the trend with repeat testing before making changes【11】.

Imaging and Additional Diagnostic Evaluation

• Obtain thyroid ultrasound and/or radionuclide scintigraphy to determine etiology (athyreosis, ectopy, or normally located gland) without delaying treatment【10】.
• Consider a knee X‑ray to assess for absent distal femoral and proximal tibial epiphyses, which indicate severe intra‑uterine hypothyroidism and predict higher neurodevelopmental risk【10】.

Neurodevelopmental Surveillance

• Recognize that treatment delayed beyond the first 2 weeks places the infant at increased risk for subtle neurocognitive deficits【11】.
• Systematically monitor psychomotor development and school progress, emphasizing that initiation of therapy within the first 2 weeks is crucial for normal intellectual outcomes【11】.

Common Pitfalls to Avoid

• Do not wait for imaging results before starting levothyroxine therapy【10】.
• Do not check TSH sooner than 4 hours after the levothyroxine dose, as this yields falsely suppressed values【11】.
• Do not use generic levothyroxine formulations in severe congenital hypothyroidism due to concerns about bioequivalence【11】.
• Do not reduce the dose based on a single elevated free T4 when TSH remains within the target range【11】.

Parental Education

• Provide written, step‑by‑step instructions on levothyroxine preparation and administration to improve adherence and reduce dosing errors【11】.